Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts

Cancer Letters
Akio OoyamaMasakazu Fukushima

Abstract

In addition to the direct cytotoxic effects of chemotherapy agents on tumor cells, the anti-angiogenic activities attained by these agents by targeting proliferating endothelial cells in tumor blood vessels has attracted much research interest. In this study, we examined the antitumor activity of 5-Fluorouracil (5-FU)-based drugs (S-1 [1M tegafur, 0.4M 5-chloro-2,4-dihydroxypyridine and 1M potassium oxonate] and capecitabine) on human colorectal cancer xenografts and evaluated their anti-angiogenic effects. Both drugs showed significant antitumor activities against COL-1 xenografts at a sub-maximum tolerated dose (sub-MTD), which was lower than the maximum tolerated dose (MTD). At the sub-MTD, a significant reduction in the microvessel number and the enhancement of tumor-associated microvessel endothelial cell apoptosis was seen in xenografts treated with S-1. In addition, we found that thrombospondin-1 (TSP-1) expression, known to be a mediator of the anti-angiogenic effects of metronomic chemotherapy, was significantly up-regulated in xenograft tumor tissues and plasma in animals treated with S-1 at a sub-MTD. Capecitabine also showed a trend toward the induction of TSP-1. These results suggest that 5-FU-based drugs inhibit t...Continue Reading

References

Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MiwaH Ishitsuka
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Y SakataT Taguchi
Jun 28, 2000·Nucleic Acids Research·A JanzA Thomas-Tikhonenko
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Feb 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R S KerbelB Kamen
Feb 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ColleoniA Goldhirsch
Mar 22, 2002·Nature·Yotaro IzumiRakesh K Jain
Apr 23, 2004·The New England Journal of Medicine·Harubumi KatoUNKNOWN Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy
May 18, 2005·Archives of Otolaryngology--head & Neck Surgery·George H YooRalph E Parchment
May 21, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G BocciM Del Tacca
Dec 8, 2005·Cancer Chemotherapy and Pharmacology·Jan-Erik DamberKlas Norrby
Nov 6, 2007·The New England Journal of Medicine·Shinichi SakuramotoUNKNOWN ACTS-GC Group
Dec 20, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Tatsuhiro IshidaHiroshi Kiwada
Oct 23, 2009·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·K MuraiT Kamataki
Dec 10, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Angelica CalleriFrancesco Bertolini

❮ Previous
Next ❯

Citations

Jun 13, 2009·European Journal of Clinical Pharmacology·Michele D MignognaStefania Leuci
Feb 4, 2011·Cancer Chemotherapy and Pharmacology·Hongju WuShasha Wang
Nov 26, 2010·Molecular Biology Reports·Maria Wisniewska-JarosinskaAlina Morawiec-Sztandera
Jun 6, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W R JarnaginN Kemeny
Dec 2, 2008·PPAR Research·Dorina VeliceasaOlga V Volpert
Dec 24, 2013·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Hiroyuki NakamuraHiroshi Kiwada
Sep 2, 2014·The Veterinary Clinics of North America. Small Animal Practice·Barbara Biller
Jun 25, 2009·Expert Opinion on Investigational Drugs·David P SamuelMark W Kieran
Oct 24, 2013·Translational Oncology·Takuji TorimuraMichio Sata
Aug 22, 2009·European Journal of Pharmacology·Anna FioravantiGuido Bocci
Dec 17, 2008·Clinical and Experimental Dermatology·A AkmanM Ozdogan
Nov 11, 2008·Oral Diseases·E HannaS K Libutti
Sep 17, 2008·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ning ZhangWei-Shan Chen
Mar 2, 2013·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Tatsuhiro Ishida, Hiroshi Kiwada
May 23, 2013·International Journal of Oncology·Tarannum FerdousYoshiya Ueyama
Sep 29, 2020·Frontiers in Physiology·Brandon N VanderVeenJames A Carson
May 30, 2020·International Journal of Molecular Sciences·Apostolos PapachristosGregory Sivolapenko
Feb 2, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karama AslehSaranya Chumsri
May 10, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Nathalia D de Moura SperottoPablo Machado
Aug 14, 2021·Advanced Drug Delivery Reviews·Victoria LaiJoshua C Doloff
Nov 18, 2017·ACS Biomaterials Science & Engineering·Leyuan XuHu Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis